Erratum to erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression

Erratum to: Transl Cancer Res 2023;12:1372-5.

In the May 2023 issue of Translational Cancer Research, the paper titled “Erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression” (Transl Cancer Res 2023;12(5):1372-1375. doi: 10.21037/tcr-23-674) (1), was published for correction of Figure 1C and Figure 5C in the article (2) published earlier. However, there are still some errors found in the aforementioned Figures 1C,5C, as well as in Figure 4C, while the figure legends for Figures 1C,5C remain intact.

The Figure 1C should be corrected as:

Figure 1 Ectopic expression of miR-3614-3p ameliorates BC migration and invasion in vitro. (C) Transwell assays (magnification 200×) showed that miR-3614-3p depressed cell metastasis (stained in 0.1% crystal violet for 15 min; upper panel: migration assays; lower panel: invasion assays).

The Figure 4C and the legend should be corrected as:

Figure 4 AKT3 and HDAC1 are experimentally validated as direct targets of miR-3614-3p in human BC cells. (C) AKT3/HDAC1 mRNA and protein expressions were assessed in MCF-7 and MDA-MB-231 cells after transfection of miR-3614 expression vector/anti-miR-3614-3p.

The Figure 5C should be corrected as:

Figure 5 AKT3 and HDAC1 are the functional mediators downstream of miR-3614-3p in BC cells. (C) Transwell assays (magnification 200×) showed that si-AKT3/HDAC1 depressed cell metastasis (stained in 0.1% crystal violet for 15 min; upper panel: migration assays; lower panel: invasion assays).

The authors confirmed that these corrections do not change the description or original conclusions of the paper and sincerely apologize for any inconvenience caused by these mistakes.

Click here to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Editorial Office. Erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression. Transl Cancer Res 2023;12:1372-5. [Crossref] [PubMed]
2. Wang Z, Jing X, Li F, et al. miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression. Transl Cancer Res 2022;11:1565-75. Erratum in: Transl Cancer Res 2023;12:1372-5. [Crossref] [PubMed]